country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P99244

Copy Link Print Information

Biologically Validated

Fezakinumab

(別名: ILV 094)

カスタマーレビュー

Based on 1 Customer Validation

Fezakinumab (ILV 094) is an anti-IL-22 monoclonal antibody. Fezakinumab inhibits IL-22 signal transduction, and regulates the JAK1/STAT3 pathway as well as apoptotic proteins. Fezakinumab alleviates airway remodeling, alveolar enlargement and inflammatory cell infiltration in lung tissues. Fezakinumab reduces the levels of neutrophils, lymphocytes, eosinophils and macrophages in lung tissues. Fezakinumab can be used in the research of chronic obstructive pulmonary disease and skin diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.9%
CAS 番号: 1007106-86-6
分子量:144.84 kDa

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Fezakinumab 構造式

CAS 番号: 1007106-86-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- 体内実験
- 臨床実験
- 遺伝子ID
- アクセッション番号
- Conjugated
- Reconsititution
- Format
- アプリケーション
- Verified Bioactivity
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Isotype

Human IgG1 lambda2

Recommend Isotype Controls

Human IgG1 lambda2, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

IL-22

JAK1

STAT3

Caspase 3

Bcl-2

Interleukin Related アイソフォーム固有の製品をすべて表示 :

JAK アイソフォーム固有の製品をすべて表示 :

STAT アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

体内実験

Fezakinumab (5 mg/kg; i.p.; once daily; 8 weeks) significantly reduces BALF T-22 cell and IL-22 levels, improves lung histopathology, and modulates JAK1/STAT3 pathway and apoptosis-related proteins to alleviate cigarette smoke-induced COPD in male C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 8-10 weeks old, 18-22 g, cigarette smoke-induced COPD model)^[1]
Dosage:

5 mg/kg
Administration:

i.p.; once daily; 8 weeks
Result:

Reduced T-22 cell levels in BALF.
Reduced IL-22 levels in BALF.
Reduced average alveolar intercept.
Increased alveolar count.
Lowered lung tissue inflammatory cell infiltration (neutrophils, lymphocytes, eosinophils, macrophages).
Reduced IL-22R1 expression in lung tissue.
Reduced lung tissue levels of JAK1, p-STAT3, Caspase3, and STAT3.
Increased lung tissue levels of Bcl-2.
Showed no significant difference in Bax and TYK2 levels compared to the CS group.
Improved lung architecture, with more uniform alveolar size, reduced airway epithelial proliferation, minimal interstitial thickening, and markedly reduced inflammatory cell infiltration.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

遺伝子ID

50616 [NCBI]

アクセッション番号

Q9GZX6

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 lambda2

アプリケーション

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized IL-22 Protein, Human (HY-P7039) can bind Fezakinumab. The EC₅₀ for this effect is 41.06 ng/mL.

化学情報

CAS 番号 1007106-86-6
性状 Liquid
分子量 144.84 kDa
Color Colorless to light yellow
SMILES

[Fezakinumab]
別名

ILV 094
輸送条件

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (260 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

参考文献

[1]. Wang Y, et al. Fezakinumab Alleviates Cigarette Smoke-Induced COPD by Suppressing the JAK1/STAT3 Pathway in Mice. Can Respir J. 2025;2025:3204642. Published 2025 Nov 29. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- 体内実験
- 臨床実験
- 遺伝子ID
- アクセッション番号
- Conjugated
- Reconsititution
- Format
- アプリケーション
- Biological Activity
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Fezakinumab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

Interleukin Related アイソフォーム固有の製品をすべて表示

JAK アイソフォーム固有の製品をすべて表示

STAT アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Fezakinumab 関連分類

HY-P99244 関連分類